Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Nestle makeover advances with $10 billion sale of skin health unit

Nestle entered exclusive talks to sell the company’s skin health business to a consortium led by EQT Partners for 10.2 billion Swiss francs ($10.1 billion), as the food group shifts its portfolio in response to changing consumer demands.

Read More »

Nivea-maker Beiersdorf buys Coppertone for $550 million

Beiersdorf, the maker of Nivea and other skin care brands, is buying U.S. sun care brand Coppertone from Bayer for $550 million to strengthen the German consumer goods firm’s position in North America.

Read More »

Sandoz, Teva Vow to Fight Price-Fixing Allegations

Teva and Novartis’ Sandoz are contesting charges stemming from a multi-state lawsuit alleging that a number of generic drugmakers conspired to manipulate prices on more than 100 drugs.

Read More »

Novartis buys dry-eye drug from Takeda for up to $5.3 billion

Novartis is buying the projected blockbuster dry-eye drug Xiidra from Takeda Pharmaceutical for up to $5.3 billion.

Read More »

Pfizer Acquires Rare-Drug Company Therachon for $810 Million

Pfizer announced plans to buy Therachon, a rare disease biotech company based in Basel, Switzerland.

Read More »

Lundbeck to acquire Abide Therapeutics

The acquisition of Abide Therapeutics Inc. will provide H. Lundbeck A/S with a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s syndrome.

Read More »

Gilead to separate Kite cell therapy unit

Gilead Sciences Inc. said Kite Pharma Inc., the cancer-focused cell therapy company acquired in 2017, will become a separate business unit.

Read More »

Catalent entering gene therapy market via Paragon buy

Catalent Inc. will buy privately held Paragon Bioservices Inc. for $1.2 billion in cash, bolstering the contract drugmaker’s capabilities to make gene therapy drugs for biotech clients.

Read More »

Bristol-Myers shareholders approve Celgene takeover

Bristol-Myers Squibb’s shareholders voted to approve the drugmaker’s $74 billion takeover of Celgene despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Read More »

Novartis lands assets from inflammation specialist IFM

Novartis agreed to pay $310 million upfront, with the possibility for more later, for some research assets of Boston-based inflammation specialist IFM Therapeutics as the Swiss drugmaker expands the company’s immunology pipeline.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom